Takeda Pharmaceutical (TAK) Equity Average: 2018-2025
Historic Equity Average for Takeda Pharmaceutical (TAK) over the last 8 years, with Mar 2025 value amounting to $48.0 billion.
- Takeda Pharmaceutical's Equity Average fell 2.65% to $47.3 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $47.3 billion, marking a year-over-year decrease of 2.65%. This contributed to the annual value of $48.0 billion for FY2025, which is 1.54% down from last year.
- Latest data reveals that Takeda Pharmaceutical reported Equity Average of $48.0 billion as of FY2025, which was down 1.54% from $48.7 billion recorded in FY2024.
- In the past 5 years, Takeda Pharmaceutical's Equity Average ranged from a high of $49.7 billion in FY2022 and a low of $46.2 billion during FY2021.
- In the last 3 years, Takeda Pharmaceutical's Equity Average had a median value of $48.7 billion in 2024 and averaged $48.5 billion.
- In the last 5 years, Takeda Pharmaceutical's Equity Average grew by 7.74% in 2022 and then declined by 1.81% in 2023.
- Takeda Pharmaceutical's Equity Average (Yearly) stood at $46.2 billion in 2021, then rose by 7.74% to $49.7 billion in 2022, then dropped by 1.81% to $48.8 billion in 2023, then fell by 0.21% to $48.7 billion in 2024, then declined by 1.54% to $48.0 billion in 2025.